Biologos, a life sciences manufacturer and portfolio company of private investor Ampersand Capital Partners, has appointed Hetal Patel as chief executive officer as the company enters its next phase of expansion under private equity ownership.
Patel, who has served as chief operating officer since 2024, takes on the role as the company ramps up investments in manufacturing capacity and capabilities aimed at supporting growth in high-value life sciences markets.
Having acquired Biologos in 2024 the leadership change is part of a broader strategy by Ampersand to scale the business across biopharma, cell and gene therapy, tissue processing and animal health sectors. As part of that expansion, the company has invested in a new 32,000-square-foot GMP-compliant manufacturing facility in Illinois designed to increase production capacity and strengthen supply reliability for customers.
Patel brings more than 25 years of experience in the life sciences sector and has played a key role in preparing the business for growth since joining the company. Her appointment coincides with the firm’s push to deepen relationships with existing customers while expanding into faster-growing biopharma and advanced therapy markets.
Founded in 1976, Biologos initially focused on the animal health sector before expanding into tissue processing in 2012 and later into biopharma and cell and gene therapy markets in 2021.
Eric Lev, general partner at Ampersand Capital Partners, said the company’s expanded capabilities and new leadership position it to accelerate growth and broaden its presence in rapidly developing life sciences segments.
